Treatment of pediatric bronchiolitis with Peginterferon α-2b injection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of inhaled Peginterferon α-2b injection in treating bronchiolitis caused by respiratory syncytial virus (RSV) in children aged 6 months to 2 years. It is a multicenter, randomized, positive-controlled, non-inferiority study that plans to enroll 90 participants. The trial will compare the effects of Peginterferon α-2b with recombinant human interferon α2b, focusing on the severity of symptoms and overall health outcomes. Participants will be monitored for adverse reactions and follow-up care will be provided as required.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The guardian of the child is able to understand the content, requirements, and limitations of the protocol, fully understands the possible adverse reactions that may occur during the study, is willing to complete the follow-up as required, and voluntarily signs the informed consent form before the start of the study.
2. The child's age is 6 months or older but no more than 2 years old (including the critical value) at the time of signing the informed consent, and the gender is not specified.
3. Positive viral detection in nasopharyngeal swab.
4. Presence of rapid breathing, wheezing, moist rales and/or wheezing sounds in the lungs; with or without chest imaging showing signs of hyperinflation, patchy infiltrates, localized atelectasis, and peribronchitis.
5. The severity of the illness is mild or moderate (evaluation criteria see Appendix 1: Wang Bronchiolitis Scoring Standard).
6. The time from the onset of the child's illness to the signing of the informed consent form is within 72 hours (the appearance of symptoms and signs related to RSV bronchiolitis does not exceed 72 hours from the signing of the informed consent, including but not limited to: tachypnea, wheezing, hypoxemia, dyspnea, fever).
7. No use of other antiviral drugs or immunomodulators within 3 weeks before randomization.

Exclusion Criteria:

1. Extreme restlessness, drowsiness, coma, and possibly requiring mechanical ventilation assistance for breathing.
2. Presence of other chronic severe diseases such as cardiac insufficiency, respiratory insufficiency, liver insufficiency, renal insufficiency, and severe malnutrition.
3. Having autoimmune diseases such as systemic lupus erythematosus or psoriasis, or immunodeficiency diseases.
4. Having epilepsy or other disorders of central nervous system function.
5. The investigator's comprehensive judgment suspects a concurrent bacterial infection.
6. Clinical diagnosis of myocarditis or suspected myocarditis (diagnostic criteria see Appendix 2: Diagnostic Recommendations for Myocarditis in Children).
7. Known or suspected allergy to interferon or excipients.
8. Participation in other interventional clinical trials within 3 months prior to screening, or planning to participate in other clinical trials during the study period. (9) A history of pneumonia in the past 3 months.

(10) Other conditions deemed unsuitable for inclusion by the investigator.

Where it's running

• Children's Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting
• Wuhan Women and Children's Health Care Center
  Wuhan, Hubei, China Not yet recruiting
• The First Hospital of Jilin University
  Changchun, Jilin, China Not yet recruiting

Study contacts

• Principal investigator: Chuangli Hao, Ph.D — Children's Hospital of Soochow University
• Study coordinator: Chuangli Hao, Ph.D
• Email: hcl_md@163.com
• Phone: 13771905555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimising Antibiotic Use for Paediatric LRTIs in Africa

  This study tests whether using point-of-care CRP tests together with the PREPARE score can safely reduce antibiotic use in infants aged 2–24 months with lower respiratory infections in a Johannesburg hospital.

  Recruiting University of Witwatersrand, South Africa · Johannesburg, Gauteng · NCT07841691

• Seawater nasal sprays for relief of nasal and sinus symptoms

  This project will test four seawater nasal sprays to see if they help infants, children, adults, and pregnant or breastfeeding people with acute or chronic nasal and sinus symptoms.

  Recruiting at 32 sites Laboratoire de la Mer · Bordeaux and 31 other locations · NCT07262450

• Understanding how genetics affect bronchodilator response in children with bronchiolitis

  This study is testing how genetics might affect how well bronchodilator treatments work for young children with bronchiolitis.

  Recruiting Phase 3 Nemours Children's Clinic · Orlando, Florida · NCT06946264

• Evaluating chest physiotherapy for infants with bronchiolitis

  This study tests if chest physiotherapy given by mothers can help infants under 12 months with bronchiolitis feel better compared to just standard hospital care.

  Recruiting Hawler Medical University · Erbil, Kurdistan · NCT06862895

• Examining low-value care in infants hospitalized with bronchiolitis

  This study looks at how often unnecessary tests and treatments are used for babies in the hospital with bronchiolitis to help improve their care and reduce costs.

  Recruiting at 7 sites St. Justine's Hospital · Calgary, Alberta and 14 other locations · NCT06506474

• Examining the link between gut bacteria and immune response in infants with bronchiolitis

  This study is trying to see how the balance of gut bacteria affects the immune response in infants with bronchiolitis caused by RSV.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Clamart and 2 other locations · NCT06161285

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.